Cardiff Oncology Inc’s recent filing unveils that its Chief Financial Officer Levine James E. acquired Company’s shares for reported $14905.0 on Dec 17 ’24. In the deal valued at $5.42 per share,2,752 shares were bought. As a result of this transaction, Levine James E. now holds 65,316 shares worth roughly $0.19 million.
Then, Levine James E. bought 2,400 shares, generating $12,000 in total proceeds. Upon buying the shares at $5.00, the Chief Financial Officer now owns 67,716 shares.
Before that, Levine James E. bought 2,564 shares. Cardiff Oncology Inc shares valued at $9,820 were divested by the Chief Financial Officer at a price of $3.83 per share. As a result of the transaction, Levine James E. now holds 62,564 shares, worth roughly $0.18 million.
Craig Hallum initiated its Cardiff Oncology Inc [CRDF] rating to a Buy in a research note published on September 06, 2024; the price target was $8. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Robert W. Baird began covering CRDF with “an Outperform” recommendation on December 08, 2021.
Price Performance Review of CRDF
On Monday, Cardiff Oncology Inc [NASDAQ:CRDF] saw its stock jump 3.56% to $2.91. Over the last five days, the stock has gained 5.82%. Cardiff Oncology Inc shares have fallen nearly -32.95% since the year began. Nevertheless, the stocks have fallen -18.49% over the past one year.
How much short interest is there in Cardiff Oncology Inc?
A steep rise in short interest was recorded in Cardiff Oncology Inc stocks on 2025-04-30, growing by 2.66 million shares to a total of 17.48 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 14.81 million shares. There was a rise of 15.23%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 22, 2020 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
